Drugs / Apramycin
Apramycin
also known as
47657 · Apramicina · Apramycine · EBL-1003 · EL-857 · Nebramycin factor 2 · Nebramycin ii · NSC-758938
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05590728 | Jun → Oct 2023 | bacterial infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT04105205 | Sep 2019 → Jul 2020 | — | Juvabis AG | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apramycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04105205 ↗ |
| Known as | 47657 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1909452 ↗ |
| Known as | Apramicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1909452 ↗ |
| Known as | Apramycine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1909452 ↗ |
| Known as | EBL-1003 | “Drug: Apramycin (EBL-1003)” NCT05590728 ↗ |
| Known as | EL-857 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1909452 ↗ |
| Known as | Nebramycin factor 2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1909452 ↗ |
| Known as | Nebramycin ii | ChEMBL registry synonym — accepted as the source's own label CHEMBL1909452 ↗ |
| Known as | NSC-758938 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1909452 ↗ |
| Modality | Small molecule | “It is a crystalline free base of the amoniglycoside apramycin.” NCT05590728 ↗ |
| Route | Intravenous | “Apramycin Administered Intravenously” NCT04105205 ↗ |